Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
|
|
Quince Therapeutics, Inc. (CRTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/27/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 05/27/2022 |
4/A
| Thye Dirk (CEO) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Granted 216,322 shares
@ $0 |
|
| 05/27/2022 |
4/A
| Hannah Brendan (Chief Business Officer) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Granted 113,569 shares
@ $0 |
|
| 11/29/2019 |
4/A
| EPIQ Capital Group, LLC (IA/Managing Member of 10% owne) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Bought 600 shares
@ $25.69, valued at
$15.4k
Bought 2,310 shares
@ $25.69, valued at
$59.3k
Bought 420 shares
@ $24.8685, valued at
$10.4k
Bought 1,635 shares
@ $24.8685, valued at
$40.7k
|
|
| 11/29/2019 |
4/A
| EPIQ Capital Group, LLC (IA/Managing Member of 10% owne) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Bought 700 shares
@ $26.3714, valued at
$18.5k
Bought 2,100 shares
@ $26.4952, valued at
$55.6k
|
|
| 11/29/2019 |
4/A
| EPIQ Capital Group, LLC (IA/Managing Member of 10% owne) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Bought 4,350 shares
@ $26.41, valued at
$114.9k
Bought 4,170 shares
@ $27.58, valued at
$115k
Bought 80 shares
@ $27.05, valued at
$2.2k
|
|
|
|